OliX Pharmaceuticals, Inc. Logo

OliX Pharmaceuticals, Inc.

Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.

226950 | KO

Overview

Corporate Details

ISIN(s):
KR7226950004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 고등동 608-3 -, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OliX Pharmaceuticals, Inc. is a clinical-stage biotechnology company that specializes in the development of novel therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric small interfering RNA (asiRNA) platform to discover and advance next-generation nucleic acid-based treatments. Its development pipeline is focused on addressing diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and metabolic disorders. Key programs in its pipeline target conditions such as hypertrophic scars, androgenetic alopecia (male-pattern baldness), age-related macular degeneration (AMD), and metabolic dysfunction-associated steatohepatitis (MASH). OliX aims to develop locally administrable therapies to improve safety and efficacy, positioning itself as an innovator in oligonucleotide therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.9 KB
2025-08-28 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-08-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 164.1 KB
2025-08-19 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 125.8 KB
2025-08-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.2 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OliX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.